SCHEMBL2604338

SCHEMBL2604338

O=C1Nc2ccccc2CCC1C1CCNCC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.45
MAPK13 O15264 1/20 0.45
MAPK12 P53778 1/20 0.45
MAPK11 Q15759 1/20 0.45
MAPK14 Q16539 1/20 0.45
MAPT P10636 1/20 0.42
PYGL P06737 5/20 0.40
PYGM P11217 5/20 0.40
AHR P35869 1/20 0.39
PDK2 Q15119 1/20 0.39
ALDH1A1 P00352 2/20 0.37
LMNA P02545 2/20 0.37
HPGD P15428 2/20 0.37
HTT P42858 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
BRD4 O60885 1/20 0.36
CREBBP Q92793 1/20 0.36
HTR2C P28335 1/20 0.36
RIPK1 Q13546 2/20 0.35
KDM4E B2RXH2 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16313799 1.00 NPC1 (0.45) NPC1MAPK13MAPK12MAPK11MAPK14
SCHEMBL2213586 0.86 CREBBP (0.44) NPC1MAPK13MAPK12MAPK11MAPK14
Hydrochloric Acid SCHEMBL3661112 0.85 CREBBP (0.43) NPC1MAPK13MAPK12MAPK11MAPK14
SCHEMBL5871094 0.74 SIGMAR1 (0.49) HTR2C
SCHEMBL9744429 0.72 PYGL (0.39) NPC1MAPK13MAPK12MAPK11MAPK14
SCHEMBL1270022 0.72 NPC1 (0.52) NPC1MAPK13MAPK12MAPK11MAPK14
SCHEMBL12598688 0.72 NPC1 (0.52) NPC1MAPK13MAPK12MAPK11MAPK14
SCHEMBL22048708 0.72 NPC1 (0.52) NPC1MAPK13MAPK12MAPK11MAPK14
SCHEMBL2214341 0.72 NPC1 (0.52) NPC1MAPK13MAPK12MAPK11MAPK14
SCHEMBL13904707 0.72 NPC1 (0.52) NPC1MAPK13MAPK12MAPK11MAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1992349-B1 CGRP antagonists, their preparation and use as a medicament BOEHRINGER INGELHEIM INT (DE) 2013-07-31 EP disclosed
US-8163737-B2 CGRP receptor antagonists VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-04-24 US disclosed
US-8163737-B2 CGRP receptor antagonists VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-04-24 US disclosed
EP-1732917-B1 SELECTED CGRP ANTAGONISTS, METHODS FOR THE PRODUCTION THEREOF AND THEIR USE AS MEDICAMENTS BOEHRINGER INGELHEIM PHARMA (DE) 2009-07-29 EP disclosed
US-20090176769-A1 CGRP RECEPTOR ANTAGONISTS VERTEX PHARMACEUTICALS INCORPORATED 2009-07-09 US disclosed
US-20090176769-A1 CGRP RECEPTOR ANTAGONISTS VERTEX PHARMACEUTICALS INCORPORATED 2009-07-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090176769-A1 CGRP RECEPTOR ANTAGONISTS CALCRL, CALCR, GRPR NPC1 488/4885MAPK13 3887/4885MAPK12 3487/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.